SNY logo

SNY
Sanofi-Aventis

5,784
Mkt Cap
$114.28B
Volume
2.94M
52W High
$60.12
52W Low
$44.62
PE Ratio
13.29
SNY Fundamentals
Price
$47.27
Prev Close
$47.04
Open
$47.69
50D MA
$48.17
Beta
0.28
Avg. Volume
3.71M
EPS (Annual)
$3.61
P/B
1.40
Rev/Employee
$582,067.48
Loading...
Loading...
News
all
press releases
Sanofi Invests $18.96 Million in Immuneering Corporation $IMRX
Sanofi bought a new stake in shares of Immuneering Corporation (NASDAQ:IMRX - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Thrivent Financial for Lutherans Increases Position in Sanofi $SNY
Thrivent Financial for Lutherans raised its position in shares of Sanofi (NASDAQ:SNY - Free Report) by 10,152.1% during the third quarter, according to its most recent disclosure with the Securities...
MarketBeat·2d ago
News Placeholder
Sanofi (NASDAQ:SNY) Rating Increased to Strong-Buy at Wall Street Zen
Wall Street Zen upgraded shares of Sanofi from a "buy" rating to a "strong-buy" rating in a research note on Saturday...
MarketBeat·3d ago
News Placeholder
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth
REGN beats Q4 earnings estimates as Eylea HD and Dupixent profits lift revenues, though higher expenses drive a year-over-year EPS decline.
Zacks·3d ago
News Placeholder
Sanofi Q4 Earnings Call Highlights
Sanofi (NASDAQ:SNY) executives told investors the company delivered strong performance in 2025 as it continued its shift toward what CEO Paul Hudson described as an R&D-driven, AI-powered biopharma...
MarketBeat·4d ago
News Placeholder
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth
Teva beats Q4 estimates driven by a Sanofi milestone and strong Austedo growth. The drugmaker also unveils its 2026 outlook.
Zacks·4d ago
News Placeholder
Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026
SNY tops Q4 earnings estimates, as Dupixent surges. It guides faster profit growth than sales in 2026, even as revenues narrowly miss
Zacks·4d ago
News Placeholder
Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth prospects and innovation...
CNBC: Top News·5d ago
News Placeholder
Sanofi Posts Q4 Loss, Sees Continued Profitable Growth In FY26; Plans EUR 1 Bln Buyback
(RTTNews) - French drug major Sanofi (SNY) reported Thursday a loss in its fourth quarter, compared to prior year's profit, despite higher net sales. Looking ahead for fiscal 2026, the company still...
Nasdaq News: Markets·5d ago
News Placeholder
Key Events This Week: Fed, Central Banks Gallore, Earnings Avalanche
Key Events This Week: Fed, Central Banks Gallore, Earnings Avalanche With the year still not yet four weeks old, it's already been a constant firehose of news volatility, even as market volatility...
Zero Hedge·7d ago
<
1
2
...
>

Latest SNY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.